title: [Compliance of film-coated praziquantel tablets in schistosomiasis transmission-controlled areas].
abstract: OBJECTIVE
  To observe the compliance of film-coated praziquantel tablets in the schistosomiasis transmission controlled areas, so as to provide the evidence for the establishment of chemotherapy intervention measures in these areas.
  
  
  METHODS
  In the areas of schistosomiasis transmission controlled in Sichuan Province, 234 people were selected as film-coated praziquantel group (FCPG), and 203 people were selected as praziquantel group (PG). A questionnaire survey was implemented and the compliance of chemotherapy of the 2 groups was compared.
  
  
  RESULTS
  In PG, all the people indicated that the praziquantel tablets has bad smell, 98.0% of the people had side-effects, such as nausea, headache, 69.5% thought the medicine was harmful to health subjectively, and 99.5% thought that it was too much dose of tablets for taking one time. In FCPG, all the people indicated that the film-coated praziquantel tablets had no bad smell, 18.8% of the people had side-effects, and 74.4% would like to choose film-coated praziquantel tablets. The rates of knowledge of praziquantel of PG and FCPG were 50.7% and 29.1%, respectively ( chi2 = 21.449, P = 0.01).
  
  
  CONCLUSIONS
  The film-coated praziquantel tablets have no bad smell and lighter side-effects. The compliance of the film-coated praziquantel tablets is high in the areas of schistosomiasis transmission controlled, so the film-coated praziquantel tablets are worth to popularize and apply.
authors.affiliation: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Laboratory of Parasite and Vector Biology, Ministry of Health, WHO Collaborating Centre for Malaria, Schistosomiasis and Filariasis, Shanghai 200025, China.
authors.forename: Chun-Li
authors.initials: CL
authors.lastname: Cao
authors.forename: Zi-Ping
authors.initials: ZP
authors.lastname: Bao
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: Ding-Hai
authors.initials: DH
authors.lastname: Wang
authors.forename: Xian-Hong
authors.initials: XH
authors.lastname: Meng
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Ying-Ying
authors.initials: YY
authors.lastname: Zhang
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Bo
authors.initials: B
authors.lastname: Zhong
authors.forename: Gen-Ming
authors.initials: GM
authors.lastname: Zhao
authors.forename: Jlia-Gang
authors.initials: JG
authors.lastname: Guo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000188:drug therapy* / Q000523:psychology* / Q000635:transmission; D013607:Tablets / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D013607:Tablets; D011223:Praziquantel